Valeant Pharmaceuticals International (pre Biovail) | Evaluate

October 13, 2010

Alexza investors right to be agitated over FDA rebuff

September 20, 2010

Event - Alexza hopes for unhindered approval of inhaled antipsychotic

August 12, 2010

Adcom recommends Potiga approval but will success be resounding?

August 03, 2010

Event - FDA on parallel track with Europe on Potiga

July 30, 2010

Acadia keeping the faith in pimavanserin despite setbacks

June 22, 2010

Biovail and Valeant join forces to drive growth

June 10, 2010

Event - Valeant’s recent efforts reduce dependence on retigabine

December 23, 2009

Who were the cash call kings of 2009?

April 23, 2009

Therapeutic focus – Tough market for new wave of epilepsy drugs

January 14, 2009

Unpartnered hep C assets to attract attention

January 09, 2009

Emergent tops slim list of stock market winners for 2008

Load More